首页> 外文期刊>Journal of Controlled Release: Official Journal of the Controlled Release Society >New drug delivery system for water-soluble drugs using silicone and its usefulness for local treatment: application of GCV-silicone to GCV/HSV-tk gene therapy for brain tumor
【24h】

New drug delivery system for water-soluble drugs using silicone and its usefulness for local treatment: application of GCV-silicone to GCV/HSV-tk gene therapy for brain tumor

机译:使用硅酮的水溶性药物的新药物递送系统及其在局部治疗中的用途:GCV-硅酮在脑肿瘤的GCV / HSV-tk基因治疗中的应用

获取原文
获取原文并翻译 | 示例
           

摘要

Controlled release of a water-soluble low-molecular-weight drug from silicone and its usefulness as a local therapeutic drug were studied. For application to ganciclovir/helpes simplex virus thymidine kinase (GCV/HSV-tk) suicide gene therapy for brain tumor, two kinds of GCV-containing silicone formulations were prepared for evaluation. In vitro. GCV release from matrix-type formulation consisting of a single matrix was characterized by Fickian diffusion, while covered-rod-type formulation, in which the side surface of the outer layer A as covered with 100% silicone, exhibited a near-zero-order release pattern. In an in vivo study using a rat 9L glioblastoma model. administration of GCV-silicone formulation into brain tumor yielded sustained intracerebral GCV concentration for 4 days after administration. with excellent antitumor effect equal to or better than that of daily intraperitoneal administration of aqueous solution of GCV, at a dose less than 1 / 100 of the total dose of solution for intraperitoneal administration. Furthermore. GCV was undetectable in blood. suggesting that decrease in systemic adverse reactions can be expected with intracerebral administration of GCV-silicone formulation. (C) 2002 Elsevier Science B.V. All rights reserved. [References: 19]
机译:研究了水溶性低分子量药物从有机硅中的控制释放及其作为局部治疗药物的用途。为了应用于更昔洛韦/单抗病毒胸苷激酶(GCV / HSV-tk)自杀基因治疗脑肿瘤,制备了两种含GCV的有机硅制剂进行评估。体外。 GCV从由单一基质组成的基质型配方中释放出来的特征在于其Fickian扩散,而包覆杆型配方中外层A的侧面被100%的有机硅覆盖,表现出接近零级的分布释放模式。在使用大鼠9L胶质母细胞瘤模型的体内研究中。在给药后4天,将GCV-硅氧烷制剂施用到脑肿瘤中产生了持续的脑内GCV浓度。每天腹膜内用GCV水溶液的抗肿瘤作用等于或优于腹膜内用药,其剂量少于腹膜内用药总剂量的1/100。此外。血液中未检测到GCV。提示通过脑内施用GCV-硅氧烷制剂可以预期减少全身不良反应。 (C)2002 Elsevier Science B.V.保留所有权利。 [参考:19]

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号